Trem2 Deficient Microglia is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TREM2-deficient microglia represent a critical state of microglial dysfunction that has emerged as a central mechanism in neurodegenerative diseases, particularly Alzheimer's disease.
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a transmembrane receptor primarily expressed on microglia in the central nervous system. Loss-of-function variants in TREM2 significantly increase the risk of developing Alzheimer's disease, with approximately 3-5-fold increased risk for heterozygous carriers of certain variants.
- Lipid Metabolism Dysregulation: TREM2 deficiency impairs microglial ability to process and clear lipid-rich debris, including myelin fragments and amyloid plaques
- Phagocytic Impairment: Reduced clearance of apoptotic cells, amyloid-beta, and other pathological aggregates
- Inflammatory Response Alteration: TREM2-deficient microglia show altered cytokine production patterns
- Metabolic Changes: Impaired metabolic adaptation to neurodegenerative microenvironments
TREM2 deficiency leads to reduced recruitment of microglia around amyloid plaques, resulting in:
- Reduced plaque compaction
- Increased diffuse amyloid deposition
- Accelerated amyloid plaque formation in early disease stages
In tau pathology models, TREM2 deficiency results in:
- Exacerbated tau propagation
- Increased neuronal tau accumulation
- Enhanced neurofibrillary tangle formation
TREM2 plays a complex role in neuroinflammation:
- Acute Response: TREM2 signaling promotes pro-inflammatory responses
- Chronic Phase: TREM2 deficiency leads to chronic, dysregulated inflammation
- TREM2 Variants: Certain TREM2 variants associated with AD show reduced signaling capacity
- Agonistic Antibodies: Monoclonal antibodies that activate TREM2 signaling are in development
- Small Molecule Activators: Compounds designed to enhance TREM2 function
- Gene Therapy: Viral vector-mediated TREM2 expression approaches
Several TREM2-targeting therapies have entered clinical trials for Alzheimer's disease, focusing on:
- Safety and tolerability
- Biomarker changes (CSF TREM2, microglia activation markers)
- Cognitive outcomes
- Trem2 Knockout Mice: Complete loss of TREM2 function
- Trem2 Conditional Knockout: Cell-type specific deletion
- AD-associated TREM2 Variant Mice: Models carrying human AD-risk variants
- iPSC-derived Microglia: From TREM2 variant carriers
- Microglia-like Cell Lines: With TREM2 modifications
The study of Trem2 Deficient Microglia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- TREM2 in neurodegeneration: evidence for a common molecular mechanism underlying Alzheimer's and Parkinson's diseases
- TREM2 deficiency leads to altered microglial function and neuronal damage
- Microglial TREM2 deficiency exacerbates alpha-synuclein pathology in Parkinson's disease models
- TREM2-targeted antibody therapeutics in clinical development for Alzheimer's disease
- Lipid metabolism in TREM2-deficient microglia
- TREM2 variants and Alzheimer's disease risk: a meta-analysis